Market Newsdesk

April 7, 2025 6:41 pm

ASUR Announces Total Passenger Traffic for March 2025

PR Newswire

Passenger traffic increased year-on-year by 13.7% in Puerto Rico, 3.1% in Colombia and decreased 3.0% in Mexico

MEXICO CITY
, April 7, 2025 /PRNewswire/ — Grupo Aeroportuario del Sureste, S.A.B. de C.V. (NYSE: ASR; BMV: ASUR), ASUR, a leading international airport group with operations in Mexico, the U.S. and Colombia, today announced that passenger traffic for March 2025 reached a total of 6.5 million passengers, representing an increase of 1.2% compared to March 2024.

Passenger traffic presented year-over-year increases of 13.7% in Puerto Rico,3.1% in Colombia, and decreased 3.0% in Mexico. Passenger traffic growth in Puerto Rico was driven by increases of 12.0% in international traffic and 13.8% in domestic traffic, while Colombia reported increases of 8.4% in international traffic and 1.6% in domestic traffic. In Mexico, a 5.7% decrease in international traffic was partially offset by a 1.1% increase in domestic traffic.

All figures in this statement reflect comparisons between the period from March 1 to 31, 2025 and from March 1 to 31, 2024. Note that last year Holy Week took place during the last week of March while this year it will take place in April. Figures exclude transit and general aviation passengers for Mexico and Colombia.

Passenger Traffic Summary
	March		*% Chg*	Year to date		*% Chg*
	2024	2025	*% Chg*	2024	2025	*% Chg*
Mexico	4,024,853	3,902,720	(3.0)	11,496,410	10,945,137	(4.8)
Domestic Traffic	1,575,299	1,593,163	1.1	4,615,085	4,580,484	(0.7)
International Traffic	2,449,554	2,309,557	(5.7)	6,881,325	6,364,653	(7.5)
San Juan, Puerto Rico	1,164,522	1,323,498	13.7	3,261,896	3,608,582	10.6
Domestic Traffic	1,044,523	1,189,079	13.8	2,935,940	3,227,246	9.9
International Traffic	119,999	134,419	12.0	325,956	381,336	17.0
Colombia	1,280,754	1,319,997	3.1	3,804,230	4,046,354	6.4
Domestic Traffic	1,004,266	1,020,202	1.6	2,963,460	3,078,656	3.9
International Traffic	276,488	299,795	8.4	840,770	967,698	15.1
Total Traffic	6,470,129	6,546,215	1.2	18,562,536	18,600,073	0.2
Domestic Traffic	3,624,088	3,802,444	4.9	10,514,485	10,886,386	3.5
International Traffic	2,846,041	2,743,771	(3.6)	8,048,051	7,713,687	(4.2)

Mexico Passenger Traffic
		March		*% Chg*	Year to date		*% Chg*
		2024	2025	*% Chg*	2024	2025	*% Chg*
Domestic Traffic		1,575,299	1,593,163	1.1	4,615,085	4,580,484	(0.7)
CUN	Cancun	789,963	794,115	0.5	2,319,681	2,287,768	(1.4)
CZM	Cozumel	19,643	16,421	(16.4)	58,503	52,559	(10.2)
HUX	Huatulco	61,155	53,880	(11.9)	176,473	160,129	(9.3)
MID	Merida	273,884	280,523	2.4	801,085	807,366	0.8
MTT	Minatitlan	9,270	12,778	37.8	28,019	36,336	29.7
OAX	Oaxaca	130,284	136,403	4.7	375,196	391,012	4.2
TAP	Tapachula	49,114	44,434	(9.5)	147,956	129,462	(12.5)
VER	Veracruz	122,306	140,281	14.7	355,729	383,896	7.9
VSA	Villahermosa	119,680	114,328	(4.5)	352,443	331,956	(5.8)
International Traffic		2,449,554	2,309,557	(5.7)	6,881,325	6,364,653	(7.5)
CUN	Cancun	2,281,525	2,142,355	(6.1)	6,410,410	5,897,448	(8.0)
CZM	Cozumel	73,439	56,983	(22.4)	190,230	150,667	(20.8)
HUX	Huatulco	26,988	27,430	1.6	80,429	80,426	(0.0)
MID	Merida	36,341	39,066	7.5	99,148	111,751	12.7
MTT	Minatitlan	517	604	16.8	1,592	1,820	14.3
OAX	Oaxaca	17,001	26,427	55.4	56,995	74,635	31.0
TAP	Tapachula	824	2,472	200.0	3,606	5,584	54.9
VER	Veracruz	10,338	10,887	5.3	30,711	33,201	8.1
VSA	Villahermosa	2,581	3,333	29.1	8,204	9,121	11.2
Traffic Total Mexico		4,024,853	3,902,720	(3.0)	11,496,410	10,945,137	(4.8)
CUN	Cancun	3,071,488	2,936,470	(4.4)	8,730,091	8,185,216	(6.2)
CZM	Cozumel	93,082	73,404	(21.1)	248,733	203,226	(18.3)
HUX	Huatulco	88,143	81,310	(7.8)	256,902	240,555	(6.4)
MID	Merida	310,225	319,589	3.0	900,233	919,117	2.1
MTT	Minatitlan	9,787	13,382	36.7	29,611	38,156	28.9
OAX	Oaxaca	147,285	162,830	10.6	432,191	465,647	7.7
TAP	Tapachula	49,938	46,906	(6.1)	151,562	135,046	(10.9)
VER	Veracruz	132,644	151,168	14.0	386,440	417,097	7.9
VSA	Villahermosa	122,261	117,661	(3.8)	360,647	341,077	(5.4)

U.S. Passenger Traffic, San Juan Airport (LMM)
	March		*% Chg*	Year to date		*% Chg*
	2024	2025	*% Chg*	2024	2025	*% Chg*
SJU Total	1,164,522	1,323,498	13.7	3,261,896	3,608,582	10.6
Domestic Traffic	1,044,523	1,189,079	13.8	2,935,940	3,227,246	9.9
International Traffic	119,999	134,419	12.0	325,956	381,336	17.0

Colombia Passenger Traffic Airplan
		March		*% Chg*	Year to date		*% Chg*
		2024	2025	*% Chg*	2024	2025	*% Chg*
Domestic Traffic		1,004,266	1,020,202	1.6	2,963,460	3,078,656	3.9
MDE	Rionegro	747,951	770,416	3.0	2,166,918	2,317,847	7.0
EOH	Medellin	97,716	91,152	(6.7)	303,345	273,442	(9.9)
MTR	Monteria	115,613	109,026	(5.7)	361,837	350,626	(3.1)
APO	Carepa	14,029	15,167	8.1	41,601	40,163	(3.5)
UIB	Quibdo	26,416	27,064	2.5	81,702	78,443	(4.0)
CZU	Corozal	2,541	7,377	190.3	8,057	18,135	125.1
International Traffic		276,488	299,795	8.4	840,770	967,698	15.1
MDE	Rionegro	276,488	299,795	8.4	840,770	967,698	15.1
EOH	Medellin
MTR	Monteria	–	–		–	–
APO	Carepa	–	–		–	–
UIB	Quibdo	–	–		–	–
CZU	Corozal	–	–		–	–
Traffic Total Colombia		1,280,754	1,319,997	3.1	3,804,230	4,046,354	6.4
MDE	Rionegro	1,024,439	1,070,211	4.5	3,007,688	3,285,545	9.2
EOH	Medellin	97,716	91,152	(6.7)	303,345	273,442	(9.9)
MTR	Monteria	115,613	109,026	(5.7)	361,837	350,626	(3.1)
APO	Carepa	14,029	15,167	8.1	41,601	40,163	(3.5)
UIB	Quibdo	26,416	27,064	2.5	81,702	78,443	(4.0)
CZU	Corozal	2,541	7,377	190.3	8,057	18,135	125.1

About ASUR
Grupo Aeroportuario del Sureste, S.A.B. de C.V. (ASUR) is a leading international airport operator with a portfolio of concessions to operate, maintain and develop 16 airports in the Americas. This comprises nine airports in southeast Mexico, including Cancun Airport, the most important tourist destination in Mexico, the Caribbean and Latin America, and six airports in northern Colombia, including Medellin international airport (Rio Negro), the second busiest in Colombia. ASUR is also a 60% JV partner in Aerostar Airport Holdings, LLC, operator of the Luis Muñoz Marín International Airport serving the capital of Puerto Rico, San Juan. San Juan’s Airport is the island’s primary gateway for international and mainland-US destinations and was the first, and currently the only major airport in the US to have successfully completed a public–private partnership under the FAA Pilot Program. Headquartered in Mexico, ASUR is listed both on the Mexican Bolsa, where it trades under the symbol ASUR, and on the NYSE in the U.S., where it trades under the symbol ASR. One ADS represents ten (10) series B shares. For more information, visit www.asur.com.mx.

View original content:https://www.prnewswire.com/news-releases/asur-announces-total-passenger-traffic-for-march-2025-302422383.html

SOURCE Grupo Aeroportuario del Sureste, S.A.B. de C.V.

April 7, 2025 6:41 pm

Encompass Health announces date of 2025 first quarter earnings call

PR Newswire

BIRMINGHAM, Ala.
, April 7, 2025 /PRNewswire/ — Encompass Health Corp. (NYSE: EHC) today announced it will report results for its first quarter ended March 31, 2025, after the market closes on Thursday, April 24, 2025. The Company will host an investor conference call at 10 a.m. ET on Friday, April 25, 2025, to discuss its results.

The conference call may be accessed by dialing 800-245-3047 and providing the conference ID EHCQ125. International callers should dial 203-518-9765 and provide the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected.

A live webcast of the conference call and an online replay of the conference call can be found on the Company’s investor website at https://investor.encompasshealth.com.

About Encompass Health

Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 167 hospitals in 38 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune’s World’s Most Admired Companies™, Becker’s Hospital Review’s 150 Top Places to Work in Healthcare and Forbes’ Most Trusted Companies in America. For more information, visit encompasshealth.com, or follow us on our newsroom, X, Instagram and Facebook.

From Fortune. © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World’s Most Admired Companies™ is trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. From Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license.

Media contact:

Polly Manuel | 205-970-5912
[email protected]

Investor Relations contact:

Mark Miller | 205-970-5860

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/encompass-health-announces-date-of-2025-first-quarter-earnings-call-302422406.html

SOURCE Encompass Health Corp.

April 7, 2025 6:40 pm

AAR names Sharon Purnell Senior Vice President and Chief Human Resources Officer

PR Newswire

WOOD DALE, Ill.
, April 7, 2025 /PRNewswire/ — AAR CORP. (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs, and OEMs, announced that Sharon Purnell has joined the Company as Senior Vice President and Chief Human Resources Officer. In this role, Purnell will oversee the Company’s global Human Resources department, including its recruitment, talent management, and engagement initiatives.

Purnell brings more than two decades of experience achieving positive human resources results through coaching and strategic leadership. She joins AAR from Stepan Company, where she served as the Chief Human Resources Officer and led development, retention, and cost saving efforts. Prior to Stepan Company, Purnell served as the Chief Human Resources Officer for Streamland Media, overseeing the integration of multiple companies and optimizing employee benefit programs. She also held Human Resources leadership positions at Riddell Sports, Underwriters Laboratories, Honeywell Aerospace, and General Electric Company.

“We are pleased to welcome Sharon to our award-winning Company culture and the Best Team in Aviation,” said Holmes.

“We are pleased to welcome Sharon to our award-winning Company culture and the Best Team in Aviation,” said John M. Holmes, AAR’s Chairman, President and CEO. “Sharon’s company integration experience and focus on talent retention are well matched to AAR’s strategic objectives.”

“I am honored to join AAR’s highly engaged team,” said Purnell. “I am ready to roll up my sleeves and build trust at all levels of the Company.”

For more information on AAR, visit aarcorp.com.

About AAR
AAR is a global aerospace and defense aftermarket solutions company with operations in over 20 countries. Headquartered in the Chicago area, AAR supports commercial and government customers through four operating segments: Parts Supply, Repair & Engineering, Integrated Solutions, and Expeditionary Services. Additional information can be found at aarcorp.com.

Contact:

Media Team
+1-630-227-5100
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/aar-names-sharon-purnell-senior-vice-president-and-chief-human-resources-officer-302422204.html

SOURCE AAR CORP.

April 7, 2025 6:38 pm

Waystar to Announce First Quarter 2025 Financial Results on April 30, 2025

PR Newswire

LEHI, Utah and LOUISVILLE, Ky., April 7, 2025 /PRNewswire/ — Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, announced today that it will report financial results for the first quarter ended March 31, 2025, after market close on Wednesday, April 30, 2025. The company will discuss its financial results on a conference call at 4:30 p.m. Eastern Time that same day.

A live audio webcast of the conference call will be available on Waystar’s investor relations website at https://investors.waystar.com/news-events/events. The webcast will be archived on the site for those unable to listen in real time.

About Waystar
Waystar’s mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals Honor Roll. Waystar’s enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.

Media Contact

Kristin Lee

[email protected]

Investor Contact

Sandy Draper

[email protected]

502-238-9511

View original content to download multimedia:https://www.prnewswire.com/news-releases/waystar-to-announce-first-quarter-2025-financial-results-on-april-30-2025-302420968.html

SOURCE Waystar

April 7, 2025 6:38 pm

The Wendy’s Company to Report First Quarter 2025 Results on May 2

PR Newswire

DUBLIN, Ohio
, April 7, 2025 /PRNewswire/ — The Wendy’s Company (Nasdaq: WEN) will release its first quarter 2025 results before the market opens on Friday, May 2.

The Company will host a conference call that same day at 8:30 a.m. ET, with a simultaneous webcast accessible from the Company’s Investor Relations website at www.irwendys.com. The related presentation materials will also be available on the Company’s Investor Relations website. The live conference call will be available by telephone at (844) 200-6205 for domestic callers and (929) 526-1599 for international callers, both using event ID 683875. A replay of the webcast will be available on the Company’s Investor Relations website.

About Wendy’s
The Wendy’s Company (Nasdaq: WEN) and Wendy’s® franchisees employ hundreds of thousands of people across more than 7,000 restaurants worldwide. Founded in 1969, Wendy’s is committed to the promise of Fresh Famous Food, Made Right, For You, delivered to customers through its craveable menu including made-to-order square hamburgers using fresh beef*, and fan favorites like the Spicy Chicken Sandwich and nuggets, Baconator®, and the Frosty® dessert. Wendy’s supports the Dave Thomas Foundation for Adoption®, established by its founder, which seeks to dramatically increase the number of adoptions of children waiting in North America’s foster care system. Learn more about Wendy’s at www.wendys.com. For details on franchising, visit www.wendys.com/franchising. Connect with Wendy’s on X, Instagram and Facebook.

*Fresh beef available in the contiguous U.S. and Alaska, as well as Canada, Mexico, Puerto Rico, the UK, and other select international markets.

Investor Contact
:

Aaron Broholm

Head of Investor Relations
(614) 764-3345; [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-wendys-company-to-report-first-quarter-2025-results-on-may-2-302422315.html

SOURCE The Wendy’s Company

April 7, 2025 6:38 pm

Jewett-Cameron to Report Fiscal 2025 Second Quarter Operational and Financial Results on April 14, 2025

NORTH PLAINS, Ore., April 07, 2025 (GLOBE NEWSWIRE) — Jewett-Cameron Trading Company Ltd. (“Jewett-Cameron”) (Nasdaq: JCTC), a company committed to innovative products that enrich outdoor spaces, will report its operational and financial results for its fiscal 2025 second quarter, after the market close on Monday, April 14, 2025. The Company has scheduled a conference call and webcast that same day, Monday, April 14, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.

Conference Call Details

Date and Time: Monday, April 14, 2025 at 4:30 p.m. Eastern time

Call-in Information: Interested parties can access the conference call by dialing (844) 836-8745 for United States callers or +1 (412) 317-6797.

Webcast Information: The webcast will be accessible live and archived at https://app.webinar.net/jaRO9VkAP6N, and accessible on the Investors section of the Company’s website at https://jewettcameron.com/pages/investor-relations.

Replay: A teleconference replay of the call will be available until April 21, 2025 at (877) 344-7529 for U.S. callers or +1 (412) 317-0088 for international callers and using replay access code 9890581.

About Jewett-Cameron Trading Company Ltd.

Jewett-Cameron Trading Company is a holding company that, through its subsidiaries, operates out of facilities located in North Plains, Oregon. Jewett-Cameron Company’s business consists of the manufacturing and distribution of patented and patent pending specialty metal and sustainable bag products, and wholesale distribution of wood products. The Company’s brands include Lucky Dog^®, for pet products; Jewett Cameron Fence for brands such as Adjust-A-Gate^®, Fit-Right^®, Perimeter Patrol^®, Euro Fence, and Lifetime Steel Pos^® for gates and fencing; MyEcoWorld^® for sustainable bag products; and Early Start, Spring Gardner, Greenline^®, and Weatherguard for greenhouses. Additional information about the Company and its products can be found on the Company’s website at www.jewettcameron.com.

Investor Contact:

Robert Blum
Lytham Partners
Phone: (602) 889-9700
[email protected]

April 7, 2025 6:38 pm

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

— Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 —

— Fresenius also licensed to sell generic bupivacaine liposome injectable suspension in the U.S. without volume limitations beginning in 2039 —

BRISBANE, Calif., April 07, 2025 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has settled its litigations with Fresenius Kabi USA, LLC (Fresenius), Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals Laboratories, Inc. related to patents for EXPAREL® (bupivacaine liposome injectable suspension).

As part of the settlement, the parties will file Consent Judgments with the United States Court of Appeals for the Federal Circuit and the United States District Courts for the District of New Jersey and the Northern District of Illinois that enjoin Fresenius from marketing generic bupivacaine liposome injectable suspension before the expiration of the patents-in-suit, except as provided for in the settlement described below.

In settlement of all outstanding claims in the litigations, Pacira has agreed to provide Fresenius with a license to Pacira’s patents required to manufacture and sell certain volume-limited amounts of generic bupivacaine liposome injectable suspension in the United States beginning on a confidential date that is sometime in early 2030. The license will permit entry of generic bupivacaine liposome injectable suspension before the July 2, 2044 expiration date of the last-to-expire of Pacira’s Orange Book-listed patents for EXPAREL.

While the agreed-upon volume-limited percentages are confidential, they begin at a high-single-digit percentage of the total volumes distributed in the U.S. market and increase gradually in each 12-month period following the volume-limited entry date until reaching a percentage in the low thirties in 2033 and increasing modestly in each of the next two 12-month periods before reaching a maximum percentage in the high thirties of the total volumes distributed in the U.S. for the final three years of the agreement. In addition, Pacira has agreed to provide Fresenius with a license to Pacira’s patents required to manufacture and sell an unlimited quantity of generic bupivacaine liposome injectable suspension in the U.S. beginning no earlier than 2039.

“We remain confident in our EXPAREL intellectual property portfolio and believe this settlement agreement appropriately recognizes the strength of our patents and provides clarity around EXPAREL exclusivity,” said Frank D. Lee, chief executive officer of Pacira. “With the litigation resolved, we look forward to focusing on advancing our 5×30 strategy and building upon our leadership position in musculoskeletal pain and adjacencies by developing new treatments that address the significant unmet needs of millions of Americans living with chronic pain.”

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera_®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Forward-Looking Statements

Any statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the settlement described herein, ‘5×30’, our growth and business strategy; our future outlook, our intellectual property and patent terms, our growth and future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH; risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and our business, including our revenues, financial condition, cash flow and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the “SEC”). In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the SEC.

Investor Contact:
Susan Mesco, (973) 451-4030
[email protected]

Media Contact:
Sara Marino, (973) 370-5430
[email protected]

April 7, 2025 6:37 pm

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) — Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX^®, one of the most widely recognized global brands. Mr. Forth has also served as a valuable contributor on Jeune’s board of directors since February 2021.

“I am excited to welcome Marc to the team as we embark on the next stage of growth at Jeune,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech and Chairman of Jeune Aesthetics. “Marc brings decades of leadership experience to Jeune, and I look forward to working with him to maximize the value of our rejuvenative aesthetics platform.”

Mr. Forth brings to Jeune wide-ranging experience as both a corporate and commercial leader in the areas of therapeutics and aesthetics. Prior to joining Jeune, Mr. Forth was President and Chief Executive Officer of AEON Biopharma, where he led the exclusive regional licensure for therapeutic use of botulinum toxin type A complex agent ABP-450 from Daewoong Pharmaceutical Co., Ltd. and then oversaw a comprehensive clinical development program for ABP-450 targeting indications in neurology, gastroenterology, and neuro/psychiatry. Before his time at AEON Biopharma, Mr. Forth was Senior Vice President of Allergan PLC and Division Head for the U.S. Neurosciences, Urology and Medical Dermatology Divisions. During his 16-year tenure at Allergan, Mr. Forth was responsible for all aspects of the commercialization of both current and future products within neurosciences, urology and medical dermatology, including BOTOX® Therapeutic. Earlier in his career, Mr. Forth led the planning and execution of the integrated marketing plans for BOTOX® Cosmetic in the United States, where he was instrumental in building out a comprehensive consumer promotional platform. Prior to Allergan, Mr. Forth held positions of increasing responsibility in sales, marketing, and public relations at TAP Pharmaceuticals and WSW Associates. Mr. Forth received a B.S. in Business Administration from California State University, Fresno and a Graduate Marketing Certification from Southern Methodist University.

“I am thrilled to be joining Jeune as CEO as it takes the next step forward in its growth journey,” said Mr. Forth. “With Krystal’s FDA-validated gene delivery platform at its core, Jeune is uniquely positioned to meet the growing demand for fundamentally rejuvenative treatments to address aging skin. I look forward to working alongside the talented team to create long-term value, drive investment, and establish Jeune as the leader in rejuvenative aesthetics.”

About Jeune Aesthetics, Inc.

Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin. For more information, please visit http://www.jeuneinc.com.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Jeune Aesthetics, Inc., including statements about the growing demand for fundamentally rejuvenative treatments to address aging skin and Jeune being uniquely positioned to meet that demand; plans to create long-term value, drive investment in Jeune, and establish Jeune as the leader in rejuvenative aesthetics; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties associated with regulatory review of clinical trials, the availability or commercial potential of Jeune’s investigative products, and such other important factors as are set forth under the caption “Risk Factors” in Krystal’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal’s and Jeune’s views as of the date of this press release. Krystal and Jeune anticipate that subsequent events and developments will cause their views to change. However, while Krystal and Jeune may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal’s and Jeune’s views as of any date subsequent to the date of this press release.

CONTACT

Investors and Media:

Stéphane Paquette, PhD
Krystal Biotech
[email protected]

April 7, 2025 6:37 pm

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kelly participated in a panel discussion at the 3rd Nasal Formulation & Delivery Summit, which took place April 1-3, 2025, in Boston, MA.

The conference brought together industry leaders to discuss the latest innovations in intranasal drug delivery, with a focus on CNS therapeutics, emergency-use treatments, and infectious disease applications. Dr. Kelly shared key insights on optimizing intranasal drug delivery, its advantages in neurological treatment, and Oragenics’ approach to improving concussion patient outcomes.

Oragenics is advancing ONP-002, a novel neurosteroid designed to treat mild traumatic brain injury (mTBI) aka concussion, leveraging intranasal administration for rapid absorption and targeted brain delivery. The company’s participation in this summit underscores its commitment to innovation in non-invasive CNS therapeutics and sharing insights with the intranasal research community.

For more information about the 3rd Nasal Formulation & Delivery Summit, visit https://www.nasal-formulation-delivery.com/.

Investor Contact

Rich Cockrell
866.889.1972
[email protected]

About Oragenics, Inc.

Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders, including its lead candidate, ONP-002, for the treatment of mild traumatic brain injury (mTBI) or concussion. The Company is also advancing proprietary powder formulations and intranasal delivery technology to enhance drug administration. For more information, visit www.oragenics.com.

April 7, 2025 6:37 pm

HBT Financial, Inc. to Announce First Quarter 2025 Financial Results on April 21, 2025

BLOOMINGTON, Ill., April 07, 2025 (GLOBE NEWSWIRE) — HBT Financial, Inc. (NASDAQ: HBT) (the “Company” or “HBT Financial”), the holding company for Heartland Bank and Trust Company, today announced that it will issue its first quarter 2025 financial results before the market opens on Monday, April 21, 2025. A copy of the press release announcing the first quarter 2025 financial results and an investor presentation will be made available on the Company’s investor relations website at https://ir.hbtfinancial.com.

About HBT Financial, Inc.

HBT Financial, Inc., headquartered in Bloomington, Illinois, is the holding company for Heartland Bank and Trust Company, and has banking roots that can be traced back to 1920. HBT Financial provides a comprehensive suite of financial products and services to consumers, businesses, and municipal entities throughout Illinois and eastern Iowa through 66 full-service branches. As of December 31, 2024, HBT Financial had total assets of $5.0 billion, total loans of $3.5 billion, and total deposits of $4.3 billion.

CONTACT:

Peter Chapman
[email protected]
(309) 664-4556